These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 22710223)
1. Resurrecting the iron age*. Shander A; Javidroozi M Crit Care Med; 2012 Jul; 40(7):2252-3. PubMed ID: 22710223 [No Abstract] [Full Text] [Related]
2. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*. Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959 [TBL] [Abstract][Full Text] [Related]
3. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Urato AC Obstet Gynecol; 2008 Sep; 112(3):703. PubMed ID: 18757678 [No Abstract] [Full Text] [Related]
4. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Toblli JE; Cao G; Oliveri L; Angerosa M Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208 [TBL] [Abstract][Full Text] [Related]
5. Clinical perspective: iron replacement therapy in chronic heart failure. Cowie MR; Lucas R Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435 [No Abstract] [Full Text] [Related]
6. Preoperative Intravenous Iron in Anemic Patients Undergoing Major Abdominal Surgery May Not PREVENTT Blood Transfusions But Still Contribute to the Objectives of Patient Blood Management. Hardy JF; Farmer SL; Auerbach M; Frank SM; Javidroozi M; Leahy MF; Meier J; Ozawa S; Shander A Anesth Analg; 2021 Apr; 132(4):1174-1177. PubMed ID: 33723195 [No Abstract] [Full Text] [Related]
7. Effectiveness of outpatient treatment with intravenous iron in selected primary Care patients. Rivilla Marugán L; Lorente Aznar T; García-Erce JA Med Clin (Barc); 2020 Jan; 154(2):66-67. PubMed ID: 30497767 [No Abstract] [Full Text] [Related]
8. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271 [TBL] [Abstract][Full Text] [Related]
9. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Van Wyck DB; Martens MG; Seid MH; Baker JB; Mangione A Obstet Gynecol; 2007 Aug; 110(2 Pt 1):267-78. PubMed ID: 17666600 [TBL] [Abstract][Full Text] [Related]
10. IV iron in heart failure: theoretical concerns need clinical confirmation. Cowie MR; Lucas R Int J Clin Pract; 2011 Sep; 65(9):1014-5. PubMed ID: 21849013 [No Abstract] [Full Text] [Related]
11. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342 [TBL] [Abstract][Full Text] [Related]
12. [Intravenous ferric carboxymaltose for the treatment of anemia in chronic renal disease]. Merino JL; Bueno B; Campos MA; Amézquita Y Rev Clin Esp (Barc); 2014; 214(5):282-3. PubMed ID: 24582410 [No Abstract] [Full Text] [Related]
13. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Seid MH; Derman RJ; Baker JB; Banach W; Goldberg C; Rogers R Am J Obstet Gynecol; 2008 Oct; 199(4):435.e1-7. PubMed ID: 18928998 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267 [TBL] [Abstract][Full Text] [Related]
15. Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron? Rineau E; Stoyanov A; Samson E; Hubert L; Lasocki S Anesth Analg; 2017 Nov; 125(5):1597-1599. PubMed ID: 28514321 [TBL] [Abstract][Full Text] [Related]
16. Use of intravenous iron supplementation in chronic kidney disease: an update. Macdougall IC; Geisser P Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137 [TBL] [Abstract][Full Text] [Related]
17. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063 [TBL] [Abstract][Full Text] [Related]
19. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Iqbal T; Stein J; Sharma N; Kulnigg-Dabsch S; Vel S; Gasche C Dig Dis Sci; 2015 May; 60(5):1375-81. PubMed ID: 25501922 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Tagboto S; Cropper L; Turner J; Pugh-Clarke K J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]